Novo Nordisk Downgrade and Prescription Weakness

On this episode of Stock Movers:

- Novo Nordisk fell as Morgan Stanley downgraded its rating to underweight on weaker prescription momentum for the firm’s weight-loss drugs.

- GSK CEO Emma Walmsley is stepping down after almost nine years with chief commercial officer Luke Miels taking over on January 1st.

- Lufthansa gained after the airline outlined new financial goals, including plans to cut 4,000 administrative jobs by 2030.

See omnystudio.com/listener for privacy information.